CompletedPhase 4

Evaluation of the Usefulness of a PRN Regimen Using Ranibizumab for Macular Edema Due to Branch Retinal Vein Occlusion

Japan27 participantsStarted 2014-01

Plain-language summary

Monthly intravitreal ranibizumab (IVR) during the first 6 month had great effect for macular edema with branch retinal vein occlusion (BVO) both in visual and anatomical outcome. It is expected that similar results could be obtained by less frequent IVR. The purpose of this study is to investigate if IVR by PRN is as effective as by monthly. In addition, the investigators are going to study the relationship between macular edema and the size and location of retinal non-perfusion area.

Who can participate

Age range50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Signed informed consent form * Macula edema secondary to BRVO * BCVA of 77 to 20 letters assessed with the use of ETDRS charts * CRT ≧250μm Exclusion Criteria: * Previous treatment with anti-VEGF drugs or corticosteroid or grid laser photocoagulation (study eye) * History of vitrectomy surgery, submacular surgery, or other surgical intervention for RVO * Ocular disorders in the study eye that may confound interpretation of study results * BCVA over 77 letters between screening and Day 0 * The pregnant or lactating woman

What they're measuring

Visual acuity

Timeframe: One years

Trial details

NCT IDNCT02478515

SponsorNagoya City University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-03

View on ClinicalTrials.gov More Branch Retinal Vein Occlusion trials